Pharmacologic treatment of schizophrenia: what the future holds (Q40489435)

21 September 2017

title

Pharmacologic treatment of schizophrenia: what the future holds (English)

1 reference

21 September 2017

0 references

Tandon R

1

1 reference

21 September 2017

Jibson MD

series ordinal

2

1 reference

21 September 2017

publication date

1 December 2001

1 reference

21 September 2017

1 reference

21 September 2017

volume

6

1 reference

21 September 2017

issue

12

1 reference

21 September 2017

page(s)

980-4, 986

1 reference

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Pharmacologic treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

An assessment of iloperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Are randomised controlled trials the only gold that glitters?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Neurocognitive impairment in schizophrenia and how it affects treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Pharmacogenetics of classical and new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Treatment-resistant schizophrenia--the role of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

Closing the gap between research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

7 January 2021

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

7 January 2021

New atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

7 January 2021

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900001097

7 January 2021

10.1017/S1092852900001097

Identifiers

DOI

1 reference

21 September 2017

1 reference